Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03571620 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients
A Phase 2 study, sponsored by Qurient Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 258
- Enrollment target
NCT03571620 is a Phase 2 study that has completed, run by Qurient Co.. The registered enrollment target is 258 participants.
The verdict
NCT03571620, a Phase 2 study, has completed, sponsored by Qurient Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 258 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to evaluate the safety and efficacy of Q301 Cream vs. vehicle in adolescent and adult subjects with mild to moderate AD. Study drug (Q301 Cream or vehicle) will be administered topically twice a day for 8 consecutive weeks.
Interventions
- DRUG Vehicle
- DRUG Q301 Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2018-06-21 |
| Est. Completion | 2020-04-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03571620
The ClinicalTrials.gov registry entry for NCT03571620 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 258 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qurient Co., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT03571620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03571620 about?
NCT03571620 is a clinical study titled "Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients". This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to evaluate the safety and efficacy of Q301 Cream vs. vehicle in adolescent and adult subjects with mild to moderate AD. Study drug (Q301 Cream or vehicle) will be administered topically twice a day for 8 consecu...
What is the current status of trial NCT03571620?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 258 participants. The study started on 2018-06-21. Estimated completion is 2020-04-21.
What interventions are being tested in trial NCT03571620?
The interventions under investigation include: Vehicle (DRUG), Q301 Cream (DRUG).
Who is sponsoring clinical trial NCT03571620?
This trial is sponsored by Qurient Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.